Dr. Alex Zhavoronkov
Insilico Medicine Inc., CEO. Biogerontology Research Foundation, CSO
Alex Zhavoronkov, PhD, is applying recent advances in artificial intelligence to aging and cancer research. He is the Chief Science Officer of the Biogerontology Research Foundation, a UK-based registered charity supporting aging research worldwide and the CEO or Insilico Medicine, Inc headquartered at the Emerging Technology Centers on the campus of the Johns Hopkins University in Baltimore. The company is focusing on applying deep learning and advanced signaling pathway activation analysis to biomarker discovery, drug discovery and drug repurposing for aging and age-related diseases.
He is also the director of the International Aging Research Portfolio (IARP) knowledge management project and head of the Regenerative Medicine Laboratory at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology, one of the largest children's cancer centers in the world performing over 300 bone marrow transplantations annually since 2012. He is the adjunct professor of the Moscow Institute of Physics and Technology and heads NeuroG, a neuroinformatics project intended to assist the elderly suffering from dementia. His primary research interests include artificial intelligence, deep learning, GPU computing, systems biology of aging, regenerative medicine, next-generation sequencing and non-invasive prenatal and cancer diagnostics.
Since 2011 he authored and co-authored over 50 publications in peer-reviewed journals and published several books including "The Ageless Generation: How advances in biomedicine will transform the global economy" (Palgrave Macmillan, 2013). Prior to switching his focus to aging research in 2004, he served as the director of Central and Eastern Europe at ATI Technologies, publicly-traded leader in computer graphics processing technologyacquired by AMD (Nasdaq:AMD).
While working for GTCbio, Dr. Zhavoronkov helped organize many biotechnology conferences in the US. Currently he is co-organizing the annual Practical Applications of Aging Research forum at the Basel Life Science Week, one of Europe's largest industry events in drug discovery.
He holds two Bachelor Degrees from Queen’ s University, a Masters in Biotechnology from Johns Hopkins University, and a PhD in Biophysics from the Moscow State University.
Latest advances in deep learning and artificial intelligence for comprehensive and accurate biomarkers of human aging:
Aging is a complex and multi-factorial disease occurring at every level of our organism.
Using latest advances in deep learning and artificial intelligence we developed a set of comprehensive and accurate biomarkers of human aging that can be used to measure the effectiveness of many interventions. We also developed a set of molecules that address these age-related changes and will be launching these soon first as nutritional supplements and later as pharmaceutical products targeting cancer and age-related diseases.